US2010016207A1PendingUtilityA1

Methods and Compositions for Raising Levels and Release of Gamma Aminobutyric Acid

45
Individually held — no corporate assignee on recordPriority: Nov 10, 2005Filed: Nov 13, 2006Published: Jan 21, 2010
Est. expiryNov 10, 2025(expired)· nominal 20-yr term from priority
Inventors:Richard J. WurtmanLei Wang
A61P 25/00A61K 38/16A61K 31/198A61P 25/28
45
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides methods of increasing the level or release of gamma aminobutyric acid (GABA) in the brain, treating Alzheimer's disease, Huntington's disease, symptoms thereof, anxiety, aggression, insomnia, cognitive or memory disturbances; seizures of any cause (e.g. idiopathic epilepsy), primary or metastatic brain tumors, depression (e.g. bipolar depression), or pain (e.g. neuropathic pain), comprising administration of glutamine, a salt thereof, or a glutamine-rich peptide. The present invention also provides methods for decreasing the level or release of GABA in the brain and treating hepatic encephalopathy, depressed consciousness, and coma, comprising decreasing dietary intake of glutamine.

Claims

exact text as granted — not AI-modified
1 . A method of increasing or stimulating a gamma aminobutyric acid (GABA) level in a brain of a subject in need thereof, comprising administering to said subject a composition comprising a glutamine, a salt thereof, or a glutamine-rich peptide, thereby increasing a GABA level in a brain of a subject in need thereof. 
   
   
       2 . The method of  claim 1 , wherein said GABA level is a striatal GABA level. 
   
   
       3 . The method of  claim 1 , wherein said administering is orally administering. 
   
   
       4 . A method of increasing or stimulating a release of a gamma aminobutyric acid (GABA) in a brain of a subject in need thereof, comprising administering to said subject a composition comprising a glutamine, a salt thereof, or a glutamine-rich peptide, thereby increasing or stimulating a release of a GABA in a brain of a subject in need thereof. 
   
   
       5 . The method of  claim 4 , wherein said release is in the striatum. 
   
   
       6 . The method of  claim 4 , wherein said release is a spontaneous or basal release. 
   
   
       7 . The method of  claim 4 , wherein said release is a glutamate-evoked release. 
   
   
       8 . The method of  claim 4 , wherein said administering is orally administering. 
   
   
       9 . A method of stimulating a gamma aminobutyric acid (GABA) receptor of a neuron in a subject in need thereof, comprising administering to said subject a composition comprising a glutamine, a salt thereof, or a glutamine-rich peptide, thereby stimulating a GABA receptor in a subject in need thereof. 
   
   
       10 . The method of  claim 9 , wherein said GABA receptor is a GABA-A receptor. 
   
   
       11 . The method of  claim 9 , wherein said GABA receptor is a GABA-B receptor. 
   
   
       12 . The method of  claim 9 , wherein said administering is orally administering. 
   
   
       13 . The method of  claim 9 , wherein said neuron is a nucleus reticularis of the thalamus (NRT) neuron. 
   
   
       14 . The method of  claim 9 , wherein said neuron is a thalamic relay neuron. 
   
   
       15 . A method of treating an epilepsy in a subject in need thereof, comprising administering to said subject a composition comprising a glutamine, a salt thereof, or a glutamine-rich peptide, thereby treating epilepsy in a subject in need thereof. 
   
   
       16 . The method of  claim 15 , wherein said epilepsy is a partial-onset epilepsy. 
   
   
       17 . The method of  claim 15 , wherein said epilepsy comprises generalized-onset seizures. 
   
   
       18 . The method of  claim 15 , wherein said administering is orally administering. 
   
   
       19 . A method for treating an Alzheimer's disease in a subject in need thereof, comprising administering to said subject a composition comprising a glutamine, a salt thereof, or a glutamine-rich peptide, thereby treating an Alzheimer's disease in a subject in need thereof. 
   
   
       20 . The method of  claim 19 , wherein said administering is orally administering. 
   
   
       21 . A method for treating a Huntington's disease or a dementia, mood disorder, or psychosis resulting therefrom in a subject in need thereof, comprising administering to said subject a composition comprising a glutamine, a salt thereof, or a glutamine-rich peptide, thereby treating a Huntington's disease or a dementia, mood disorder, or psychosis resulting therefrom in a subject in need thereof. 
   
   
       22 . The method of  claim 21 , wherein said administering is orally administering. 
   
   
       23 . A method of treating an anxiety disorder or decreasing an incidence of aggression in a subject in need thereof, comprising administering to said subject a composition comprising a glutamine, a salt thereof, or a glutamine-rich peptide, thereby treating an anxiety disorder or decreasing an incidence of aggression in a subject in need thereof. 
   
   
       24 . The method of  claim 23 , wherein said administering is orally administering. 
   
   
       25 . A method of treating an insomnia or producing sedation in a subject in need thereof, comprising administering to said subject a composition comprising a glutamine, a salt thereof, or a glutamine-rich peptide, thereby treating an insomnia or producing sedation in a subject in need thereof. 
   
   
       26 . The method of  claim 25 , wherein said administering is orally administering. 
   
   
       27 . A method of decreasing a gamma aminobutyric acid (GABA) level in a brain of a subject in need thereof, comprising decreasing a dietary intake of glutamine by said subject, or contacting said subject with a compound or composition that suppresses glutamine transport across the blood-brain barrier, thereby decreasing a GABA level in a brain of a subject in need thereof. 
   
   
       28 . The method of  claim 27 , wherein said GABA level is a striatal GABA level. 
   
   
       29 . A method of decreasing a release of a gamma aminobutyric acid (GABA) in a brain of a subject in need thereof, comprising decreasing a dietary intake of glutamine by said subject, or contacting said subject with a compound or composition that suppresses glutamine transport across the blood-brain barrier, thereby decreasing a release of a GABA in a brain of a subject in need thereof. 
   
   
       30 . The method of  claim 29 , wherein said release is in the striatum. 
   
   
       31 . The method of  claim 29 , wherein said release is a spontaneous or basal release. 
   
   
       32 . The method of  claim 29 , wherein said release is a glutamate-evoked release. 
   
   
       33 . A method of treating a depressed consciousness or coma in a subject in need thereof, comprising decreasing a dietary intake of glutamine by said subject, or contacting said subject with a compound or composition that suppresses glutamine transport across the blood-brain barrier, thereby treating a depressed consciousness or coma in a subject in need thereof. 
   
   
       34 . The method of  claim 33 , wherein said depressed consciousness or coma is associated with a liver cirrhosis. 
   
   
       35 . A method of treating a hepatic encephalopathy in a subject in need thereof, comprising decreasing a dietary intake of glutamine by said subject, or contacting said subject with a compound or composition that suppresses glutamine transport across the blood-brain barrier, thereby treating a hepatic encephalopathy in a subject in need thereof. 
   
   
       36 . A method of decreasing stimulation of a gamma aminobutyric acid (GABA) receptor of a neuron in a subject in need thereof, comprising decreasing a dietary intake of glutamine by said subject, or contacting said subject with a compound or composition that suppresses glutamine transport across the blood-brain barrier, thereby decreasing stimulation of a GABA receptor in a subject in need thereof. 
   
   
       37 . The method of  claim 36 , wherein said GABA receptor is a GABA-A receptor. 
   
   
       38 . The method of  claim 36 , wherein said GABA receptor is a GABA-B receptor. 
   
   
       39 . The method of  claim 36 , wherein said neuron is a nucleus reticularis of the thalamus (NRT) neuron. 
   
   
       40 . The method of  claim 36 , wherein said neuron is a thalamic relay neuron.

Join the waitlist — get patent alerts

Track US2010016207A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.